#United States #Boston #RxTran #Language Scientific #Transduction

RxTran's Second Patent: A Leap Forward in Patient Communication

On September 17, 2026, Language Scientific celebrated a major achievement as it was awarded its second patent for RxTran's innovative Transduction technology, designed to improve communication in pharmacies and healthcare setups where language barriers exist. The U.S. Patent and Trademark Office officially recognized the innovation that enables pharmacists to verify translations of medicine instructions even when they cannot read the original language. This monumental advancement, marked by Patent US 12,602,554, encapsulates a broader vision of patient safety, especially for those with limited English proficiency.

Enhancing the Pharmacist’s Role in Communication

Leonid Fridman, the Founder and President of Language Scientific and RxTran, emphasizes the crucial distinction between speed and accuracy in translation. While free translation tools offer quick outputs, they fall short of providing the accuracy needed to ensure patient safety. RxTran's system allows pharmacists to maintain the reins of communication, confirming the meanings of instructions in their language before they are dispensed to patients. This method ensures that patients receive verified, comprehensible instructions rather than potentially dangerous mistranslations.

How the Transduction Technology Works

Unlike conventional systems that require pharmacists to understand the target language, RxTran employs a unique method that deconstructs original language instructions into semantic structures. These structures are then mapped against a library of pre-translated phrases. The pharmacist reviews the meaning first in their language before the system generates a verified translation. This process allows pharmacists, even those who speak only English, to confirm translations in common languages like Vietnamese accurately.

Addressing Limitations of Free Translation Tools

The common practice of checking translations by converting them back into English can lead to inaccuracies due to reliance on sentence-match algorithms. Such tools might return the same wording even when the patient's version is incorrect, potentially putting patient safety at risk. RxTran's patent addresses this significant gap by ensuring that unreliable translation outputs do not enter the patient communication chain, thereby prioritizing safety.

New Features in RxTran's Second Patent

This recent patent not only extends the existing capabilities of RxTran's technology but introduces exciting new functionalities. A correction loop feature allows pharmacists to modify translations and submit them back for verification, ensuring that even the input can be refined. Additionally, machine-learning models will now intelligently identify and rank the best translation candidates, enhancing the accuracy of selected translations.

Furthermore, this patent introduces a speech input function. Pharmacists can dictate instructions directly into the system, streamlining the communication process. Overall, these advancements mark a significant enhancement in ensuring the precision of pharmacological instructions across various languages.

Impact on Patients with Limited English Proficiency

In the U.S., over 28 million residents face limited English proficiency, which poses a substantial challenge in healthcare settings, where clear communication is vital. Studies have suggested that such patients are 33% more likely to be readmitted to hospitals within a week, highlighting the urgent need for reliable translation methods. Federal guidelines stipulate that any machine translation of critical documents must undergo qualified human review, a standard that many free tools fall short of.

Broader Implications of the Patent

Beyond pharmacy labels, the patent covers a comprehensive method for enhancing communication with limited English speakers in several healthcare situations, including hospital discharge instructions and urgent care situations. RxTran's focus on the underlying method ensures that any instance requiring verified translation is adequately supported and reliable.

Quality Assurance and Trusted Collaborations

RxTran utilizes a stringent five-step quality control process to ensure the translations are validated by licensed pharmacists, affirming the reliability of their extensive library containing over one million pre-translated phrases in 26 languages. Furthermore, RxTran integrates seamlessly with various pharmacy software systems, including systems used across both independent and chain pharmacies, ensuring accessibility for all healthcare providers.

Commitment to Patient Safety

As RxTran continues to innovate and expand its offerings, its commitment remains firm in enhancing patient safety and communication. This new patent reflects a growing recognition within the healthcare sector of the importance of catering to diverse linguistic backgrounds. More than ever, ensuring that patients understand their treatment regimens in their language is imperative for better health outcomes.

In summary, RxTran’s technology not only revolutionizes the way pharmacists interact with non-English-speaking patients but also fortifies the critical intersection of language and healthcare delivery. For further insights, RxTran's upcoming white paper will delve deeper into the requirements for patient safety and the inadequacies of unverified machine translations.